NDA 209139 · Carmel Biosciences
Prexxartan
Valsartan · Oral · Angiotensin 2 Receptor Blocker
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Dec 19, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
499
141 Phase 3, 34 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue PREXXARTAN TM as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 ) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue PREXXARTAN TM as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
What it is approved for
From the label in effect Sep 24, 2026.
PREXXARTAN™ is an angiotensin II receptor blocker (ARB) indicated for: • Hypertension in adults and children six years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV); PREXXARTAN™ significantly reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets ( 1.2 ) • Post-myocardial infarction , stable left ventricular failure or left ventricular dysfunction following myocardial infarction; PREXXARTAN™ reduces cardiovascular mortality in patients who are unable to swallow valsartan tablets ( 1.3 ) 1.1 Hypertension PREXXARTAN™ is indicated for the treatment of hypertension in adults and children six years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of...
Mechanism: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PREXXARTAN · VALSARTAN 4MG/ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Valsartan" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential HypertensionPivotal-lookingCompleted
Oslo University HospitalAcademic, hospital or other
NCT06395194 · 15,313 participants · Start Sep 27, 1997 · Primary completion Sep 5, 2003
Drug: Cardiac outcomes on treatment with valsartan; Cardiac outcomes on treatment with amlodipine · For: Essential Hypertension
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular ComplicationsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00097786 · 9,306 participants · Start Jan 2002 · Primary completion Oct 2009
Drug: Valsartan 160 mg + nateglinide 60 mg; Valsartan 160 mg + nateglinide placebo and 2 more · For: Diabetes Mellitus, Type 2
Sites: Multiple Locations, New Jersey; Investigative Site, Argentina; Investigative Site, Australia · 38 sites in all
- Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)Pivotal-lookingRecruiting
Hospital Moinhos de VentoAcademic, hospital or other
NCT05155137 · 8,518 participants (planned) · Start Dec 20, 2021 · Primary completion Dec 14, 2029
Drug: Drug Capsule (Valsartan + Amlodipine + Rosuvastatin) · For: Stroke; Cognitive Decline
Sites: Porto Alegre, Brazil · 2 sites in all
- This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailurePivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01035255 · 8,442 participants · Start Dec 2009 · Primary completion May 2014
Drug: LCZ696 200 mg BID; Enalapril 10 mg BID · For: Heart Failure With Reduced Ejection Fraction
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,031 sites in all
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPillPivotal-lookingCompleted
Tehran University of Medical SciencesAcademic, hospital or other
NCT01271985 · 8,410 participants · Start Feb 2011 · Primary completion Jan 2019
Drug: PolyPill · For: Cardiovascular Diseases
Sites: Gonbad, Iran
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Anand IS, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.
Shaddy R, Burch M, Kantor PF, et al. · Circulation 2024 · Randomized Controlled Trial, Multicenter Study
- [The PARAGON-HF trial].
Tridetti J, Nguyen Trung ML, Ancion A, et al. · Rev Med Liege 2020 · Multicenter Study, Randomized Controlled Trial
- Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ, Morrow DA, DeVore AD, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
Morrow DA, Velazquez EJ, Desai AS, et al. · J Am Coll Cardiol 2024 · Randomized Controlled Trial
- A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients.
Qian J, Zhang M, Chen Z · Adv Ther 2024 · Systematic Review, Comparative Study
Sponsor: Carmel Biosciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.